Literature DB >> 28728676

Efficacy of Esketamine in the Treatment of Depression With Psychotic Features: A Case Series.

Elias Ajub1, Acioly L T Lacerda2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28728676     DOI: 10.1016/j.biopsych.2017.06.011

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


× No keyword cloud information.
  6 in total

Review 1.  Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review.

Authors:  P Molero; J A Ramos-Quiroga; R Martin-Santos; E Calvo-Sánchez; L Gutiérrez-Rojas; J J Meana
Journal:  CNS Drugs       Date:  2018-05       Impact factor: 5.749

2.  Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial.

Authors:  Fernanda S Correia-Melo; Gustavo C Leal; Michelle S Carvalho; Ana Paula Jesus-Nunes; Carolina B N Ferreira; Flávia Vieira; Guilherme Magnavita; Lucas A S Vale; Rodrigo P Mello; Carolina Nakahira; Felipe C Argolo; Tanise Cardoso; Cezar D S Souza; Ana Teresa C Fontes; Marcelo B Ferreira; Lucas Araújo-de-Freitas; Marco A Tuena; Mariana V F Echegaray; Diogo E Cavalcanti; Ana C Lucchese; Igor D Bandeira; Manuela Telles; Cássio S Lima; Aline S Sampaio; Samantha S Silva; Roberta F Marback; José A Del-Porto; José Neander Abreu; Luciana M Sarin; Camilla S Paixão; Lucas P Carvalho; Paulo R L Machado; Gustavo Turecki; Acioly L T Lacerda; Lucas C Quarantini
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

3.  Tyrosine 121 moves revealing a ligandable pocket that couples catalysis to ATP-binding in serine racemase.

Authors:  Chloe R Koulouris; Sian E Gardiner; Tessa K Harris; Karen T Elvers; S Mark Roe; Jason A Gillespie; Simon E Ward; Olivera Grubisha; Robert A Nicholls; John R Atack; Benjamin D Bax
Journal:  Commun Biol       Date:  2022-04-11

4.  The antidepressant effect and safety of non-intranasal esketamine: A systematic review.

Authors:  Sanne Y Smith-Apeldoorn; Maurice Vischjager; Jolien Ke Veraart; Jeanine Kamphuis; Marije Aan Het Rot; Robert A Schoevers
Journal:  J Psychopharmacol       Date:  2022-05-12       Impact factor: 4.562

5.  Case report: Intranasal esketamine for severe major depressive disorder with psychotic features.

Authors:  Maximilian Carter; Kassandra Solsrud; Nicholas Mischel
Journal:  Front Psychiatry       Date:  2022-07-25       Impact factor: 5.435

6.  Bio-behavioural changes in treatment-resistant socially isolated FSL rats show variable or improved response to combined fluoxetine-olanzapine versus olanzapine treatment.

Authors:  K Mncube; B H Harvey
Journal:  IBRO Neurosci Rep       Date:  2022-09-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.